Peter Johnson mainly focuses on Internal medicine, Lymphoma, Rituximab, Surgery and Follicular lymphoma. His Internal medicine research includes elements of Gastroenterology and Oncology. The concepts of his Lymphoma study are interwoven with issues in Germinal center, Cancer research and Radiation therapy.
His work deals with themes such as CHOP, B cell and CD20, which intersect with Rituximab. His research in Surgery tackles topics such as Tolerability which are related to areas like Standard treatment, Working Formulation and Aggressive lymphoma. His Follicular lymphoma study incorporates themes from Mutation, B-cell lymphoma, Biopsy and Bone marrow.
His scientific interests lie mostly in Internal medicine, Lymphoma, Oncology, Cancer research and Surgery. As part of his studies on Internal medicine, he often connects relevant subjects like Gastroenterology. As part of his Pathology and Immunology and Lymphoma studies, he is studying Lymphoma.
His Oncology study integrates concerns from other disciplines, such as ABVD and Hodgkin lymphoma. Regimen is the focus of his Surgery research. His Immunotherapy research integrates issues from Antibody and Monoclonal antibody.
Peter Johnson focuses on Internal medicine, Oncology, Lymphoma, Cancer research and Diffuse large B-cell lymphoma. His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery. Peter Johnson combines subjects such as Cancer, Chemotherapy, Hodgkin lymphoma, Proportional hazards model and CD20 with his study of Oncology.
Peter Johnson has included themes like Positron emission tomography and Precision medicine in his Lymphoma study. His research in Cancer research intersects with topics in Ibrutinib and Chronic lymphocytic leukemia. Peter Johnson focuses mostly in the field of Diffuse large B-cell lymphoma, narrowing it down to topics relating to Rituximab and, in certain cases, Prednisone and Chlorambucil.
His main research concerns Internal medicine, Lymphoma, Oncology, Rituximab and Diffuse large B-cell lymphoma. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery. His Surgery research incorporates themes from Odds ratio and Hazard ratio.
His research investigates the connection between Lymphoma and topics such as Radiation therapy that intersect with issues in Hodgkin lymphoma and Chemotherapy. His research investigates the connection with Rituximab and areas like Prednisone which intersect with concerns in Cyclophosphamide and Ibrutinib. The Diffuse large B-cell lymphoma study combines topics in areas such as Bortezomib, Neutropenia and Germinal center, B cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang;Simon Rule;Peter Martin;Andre Goy.
The New England Journal of Medicine (2013)
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier;C. Haioun;N. Ketterer;A. Engert.
European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma
James M. Foran;Ama Z. S. Rohatiner;David Cunningham;Razvan A. Popescu.
Journal of Clinical Oncology (2000)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan.
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford;Tim Illidge;Nicholas Counsell;Barry Hancock.
The New England Journal of Medicine (2015)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly;M Gomes da Silva;U Vitolo;A Jack.
Annals of Oncology (2012)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson;Massimo Federico;Amy A Kirkwood;Alexander Fossa.
The New England Journal of Medicine (2016)
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
David Cunningham;Eliza A Hawkes;Andrew Jack;Wendi Qian.
The Lancet (2013)
Clinical trials of antibody therapy.
Martin J Glennie;Peter W.M Johnson.
Immunology Today (2000)
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni.
The Lancet Haematology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: